Eventide Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Eventide Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,970,000	Closed	-$13.9M	–	154
2023 Q3	$13.9M	Hold	1,970,000	–	–	0.25%	105
2023 Q2	$13.9M	Buy	1,970,000 +867,111	+79%	+$6.96M	0.23%	107
2023 Q1	$9.2M	Buy	+1,102,889	New	+$10.6M	0.17%	118
2019 Q1	–	Sell	-1,047,000	Closed	-$8.45M	–	132
2018 Q4	$8.45M	Hold	1,047,000	–	–	0.37%	72
2018 Q3	$7.99M	Buy	+1,047,000	New	+$7.03M	0.29%	86
2018 Q1	–	Sell	-290,000	Closed	-$1.42M	–	145
2017 Q4	$1.42M	Hold	290,000	–	–	0.07%	118
2017 Q3	$1.52M	Hold	290,000	–	–	0.09%	111
2017 Q2	$1.61M	Buy	+290,000	New	+$1.77M	0.1%	101

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eventide Asset Management's BCRX Position: Q4 2023 in Review

Eventide Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 1,970,000 shares — an estimated $13.9M sold.

Eventide Asset Management first reported a position in BCRX in Q2 2017 and held it in 8 quarters. The position peaked at $13.9M in Q3 2023. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

Eventide Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Eventide Asset Management sold 1,970,000 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $13.9M.
Eventide Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Eventide Asset Management's BioCryst Pharmaceuticals position peaked at $13.9M in Q3 2023.
235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.